Back to funds
View filing
ARCH Venture Management, LLC
hedge fundUpdated 27 days agoManaged by Arch Venture Management, Llc • Latest filing Q2 2026
Portfolio value
$1.1B
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
67.2%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $207.2M |
| Q2 2023 | $162M |
| Q3 2023 | $154M |
| Q4 2023 | $163.5M |
| Q1 2024 | $80.3M |
| Q2 2024 | $266M |
| Q3 2024 | $260.6M |
| Q4 2024 | $230.2M |
| Q1 2025 | $206.2M |
| Q2 2025 | $299.1M |
| Q3 2025 | $492.4M |
| Q4 2025 | $651.7M |
| Q1 2026 | $677.1M |
| Q2 2026 | $1.1B |
Top holdings
12 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | P PBLS PARABILIS MEDICINES INC | $175.5M | 6.41M | 15.95% | — |
| 2 | B BEAM BEAM THERAPEUTICS INC | $155.8M | 4.54M | 14.16% | Unchanged |
| 3 | R RAPP RAPPORT THERAPEUTICS INC | $155.4M | 3.73M | 14.12% | Unchanged |
| 4 | ? N/A SEAPORT THERAPEUTICS INC | $136.6M | 6.29M | 12.42% | — |
| 5 | E EQR ERASCA INC | $129.9M | 7.09M | 11.81% | Unchanged |
| 6 | V VIR VIR BIOTECHNOLOGY INC | $129.4M | 12.69M | 11.76% | Trimmed(-1.7%) |
| 7 | M MAZE MAZE THERAPEUTICS INC | $123M | 4.12M | 11.18% | Unchanged |
| 8 | L LYEL LYELL IMMUNOPHARMA INC | $45.5M | 3.25M | 4.14% | Unchanged |
| 9 | G GENB GENERATE BIOMEDICINES INC | $32.8M | 1.94M | 2.98% | Unchanged |
| 10 | T TXG 10X GENOMICS INC | $8.4M | 217.8K | 0.76% | Unchanged |
| 11 | ? N/A BOUNDLESS BIO INC | $6.7M | 2.69M | 0.61% | — |
| 12 | G GOSS GOSSAMER BIO INC | $1.3M | 8.06M | 0.12% | Unchanged |